<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJEMD</journal-id><journal-title-group><journal-title>Open Journal of Endocrine and Metabolic Diseases</journal-title></journal-title-group><issn pub-type="epub">2165-7424</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojemd.2023.1310014</article-id><article-id pub-id-type="publisher-id">OJEMD-129264</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Correlation between Pubertal Delay in Adolescents with Homozygous Sickle Cell Disease and Socio-Demographic, Clinical Factors
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nestor</surname><given-names>Ghislain Andzouana Mbamognoua</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>John</surname><given-names>Claude Edzan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Farel</surname><given-names>Ongoth Elilie Mawa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Judicael</surname><given-names>Kambourou</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lydie</surname><given-names>Ocini Ngolet</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Henri</surname><given-names>Germain Monabeka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Congo</addr-line></aff><aff id="aff2"><addr-line>Pediatric Intensive Care Department, Brazzaville University Hospital, Brazzaville, Congo</addr-line></aff><aff id="aff1"><addr-line>Department of Metabolic and Endocrine Diseases, Brazzaville University Hospital, Brazzaville, Congo</addr-line></aff><pub-date pub-type="epub"><day>23</day><month>11</month><year>2023</year></pub-date><volume>13</volume><issue>10</issue><fpage>173</fpage><lpage>190</lpage><history><date date-type="received"><day>5,</day>	<month>August</month>	<year>2023</year></date><date date-type="rev-recd"><day>28,</day>	<month>October</month>	<year>2023</year>	</date><date date-type="accepted"><day>31,</day>	<month>October</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial International License (CC BY-NC).http://creativecommons.org/licenses/by-nc/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction:
   Pubertal development is a process leading to the acquisition of reproductive capacities. Among the factors that inhibit pubertal development are chronic diseases including sickle cell anemia, which is a public health problem. <b>Objectives:</b> Describe the sociodemographic and clinical characteristics of adolescents with sickle cell disease. Report the prevalence of abnormalities of pubertal development. Identify associated factors that delay pubertal development. <b>Patients and Methods:</b> This was a multicenter analytical cross-sectional study over 7 months at the National Reference Center for Sickle Cell Disease and, at the Brazzaville University Hospital. It concerned adolescents with sickle cell disease aged between 10 to 19 years. The study focused on the sociodemographic characteristics of adolescents, the natural history of sickle cell anemia and the evaluation of secondary sexual characteristics using the Tanner classification. Nutritional status was assessed by calculating body mass index (BMI) and height/age and weight/age ratios. <b>Results:</b> Of the 347 adolescents included, the average age of the adolescents was 15.1 &#177; 2.5 years, 56.5% had normal puberty, 42.6% had delayed puberty and 0.9% had impuberty. The associated factors were under-nutrition with less than 3 meals/day (p = 0.0000), social status with more marked pubertal delay in orphans (p = 0.00127), more than 5 hospitalizations per year (p = 0.0013), pubertal delay was statistically significant in adolescents who had more than 3 vaso-occlusive crises (p = 0.0000), and those who had more than 5 blood transfusions since the discovery of the disease (p = 0.0127). <b>Conclusion</b>: The factors that hinder pubertal development in sickle cell patients are intrinsic (sickle cell anemia with its complications) and extrinsic (environmental: diet, social status). The appearance of secondary sexual characteristics is delayed on average by two years compared to the general population.
 
</p></abstract><kwd-group><kwd>Development</kwd><kwd> Puberty</kwd><kwd> Adolescent</kwd><kwd> Sickle Cell Disease</kwd><kwd> Homozygous</kwd><kwd> Brazzaville</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Pubertal development represents a physical, biological and psychological process, which results in the acquisition of reproductive capacities [<xref ref-type="bibr" rid="scirp.129264-ref1">1</xref>] . Abnormalities of pubertal development constitute a frequent reason for consultation [<xref ref-type="bibr" rid="scirp.129264-ref2">2</xref>] . Pubertal development is regulated by activating and inhibitory factors. Among the factors inhibiting pubertal development are chronic diseases including sickle cell anemia, the leading hemoglobinopathy in the world and which is a public health problem [<xref ref-type="bibr" rid="scirp.129264-ref3">3</xref>] .</p><p>Several studies report that sickle cell disease is responsible for endocrine complications in adolescence, including growth retardation and pubertal delay [<xref ref-type="bibr" rid="scirp.129264-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref5">5</xref>] .</p><p>Hospital statistics for pubertal delay in adolescents living with homozygous sickle cell disease vary worldwide, ranging from 8% to 50% in Europe and 15% in Latin America [<xref ref-type="bibr" rid="scirp.129264-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref6">6</xref>] . In Africa, the reported data confirm the same trends, particularly in Egypt: 25% and Nigeria: 75% [<xref ref-type="bibr" rid="scirp.129264-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref8">8</xref>] .</p><p>In Congo, studies carried out on patients living with homozygous sickle cell disease show high prevalence of delayed puberty ranging from 28.7% to 53.7% and therefore constitutes a worrying health problem [<xref ref-type="bibr" rid="scirp.129264-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref10">10</xref>] .</p><p>Some factors influencing pubertal development in adolescents living with homozygous sickle cell disease such as inadequate nutritional intake and deficiencies in essential micronutrients are preventable [<xref ref-type="bibr" rid="scirp.129264-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref12">12</xref>] . Several questions remain open, namely how many Congolese adolescents living with homozygous sickle cell disease are vulnerable to good pubertal development and what are the conditions, or even the internal and/or external predispositions (factors) which are unfavorable or protective for normal pubertal development.</p><p>It is therefore necessary for these factors to be known to practitioners in order to integrate them into the overall management of sickle cell disease. It is in this perspective that we set ourselves the general objective of studying the pubertal development of adolescents living with homozygous sickle cell disease in Brazzaville, and more specifically:</p><p>1) Describe the sociodemographic and clinical characteristics of adolescents living with homozygous sickle cell disease in Brazzaville;</p><p>2) Report the prevalence of abnormalities of pubertal development in adolescents living with homozygous sickle cell disease in Brazzaville;</p><p>3) Identify the sociodemographic and clinical factors that delay the pubertal development of adolescents living with homozygous sickle cell disease in Brazzaville.</p></sec><sec id="s2"><title>2. Patients and Methods</title><p>This was a multicenter analytical cross-sectional study with prospective data collection. The study took place from April 1st to October 30th, 2022, in seven months. The study was conducted in the following health centers: The National Reference Center for Sickle Cell Disease, the Pediatrics Department of the Brazzaville Hospital and University. During the study period, 982 patients living with sickle cell disease were seen on an outpatient or inpatient basis at the selected health facilities, including 353 adolescents. The inclusion criteria were: only adolescents, in accordance with the WHO definition of an adolescent as any person aged between 10 and 19 years [<xref ref-type="bibr" rid="scirp.129264-ref13">13</xref>] , The inclusion criteria were: only adolescents according to the WHO definition which considers as adolescents any person between the ages of 10 and 19 years [<xref ref-type="bibr" rid="scirp.129264-ref13">13</xref>] , having performed a blood count and received prior consent from the parent/guardian for minors or having consented to participate in the study for adults. Exclusion criteria among adolescents were: another known chronic pathology (congenital heart disease, respiratory insufficiency, HIV/AIDS infection, endocrinopathies) that may affect growth; living adolescents with homozygous sickle cell disease in a gestational state. 6 adolescents were excluded for a total of 347 adolescents participating in the study.</p><p>The data was collected using a survey form (Appendix I) including a questionnaire on the sociodemographic characteristics of the adolescent, the natural history of sickle cell disease (completed by the adolescent’s follow-up form or diary) and the age of onset of certain secondary sexual characteristics; A physical examination including Anthropometric measurements including weight and height for assessment of nutritional status and growth. Nutritional status was assessed by calculating body mass index (BMI) and height/age and weight/age ratios. Wasting: when the BMI/A ratio, relative to the WHO standard deviation curves, is between −3DS and −2DS, Severe wasting: when the BMI/A ratio, relative to the WHO standard deviation curves, is below −3DS.</p><p>All these measurements were related to the new WHO growth curves (Appendix II). Assessment of pubertal development using the Tanner classification (Appendix III). This study was carried out after obtaining informed consent from the parents and the agreement of an ethics committee (Appendix IV) in accordance with the Helsinki declaration. The variables related to the adolescent were sociodemographic: age (in year and month), sex, social status (orphan or not), diet (number of meals per day); and clinical: circumstances of discovery of the disease, number of hospitalizations/year, number of transfusion episodes since discovery of the disease, status of acute and chronic complications, splenectomy, nutritional status: (P, T, BMI); age of onset of secondary sexual characteristics (thelarche, menarche, pubarche, spermache, gynecomastia); pubertal stage according to Tanner’s Classification. The survey data were entered using Microsoft Excel version 2013. SPSS version 20 was used to process and analyze the data. Central tendency parameters were used to describe the quantitative variables. For the univariate analysis, the significance threshold of 5% was considered in the search for potential risk factors. Thus a correlation exists between two variables when the p-value is less than or equal to 0.05.</p></sec><sec id="s3"><title>3. Results</title><p>In our study, 347 adolescents living with homozygous sickle cell disease were registered out of 353 homozygous sickle cell adolescents during the study period. The participation rate was 98.3%. The adolescents were on average aged 15.1 &#177; 2.5 years with extremes of 10 and 19 years. Their distribution according to age groups (in years) is recorded in <xref ref-type="table" rid="table1">Table 1</xref>.</p><p>At the end of the study, 182 (52.4%) adolescents were male and 165 (47.6%) female, i.e. a sex ratio = 1.1</p><p>Fifty-six (16.1%) adolescents selected for the study were orphans, 48 of whom were single-parent orphans and 8 were two-parent orphans. The diet of adolescents living with sickle cell disease was varied for 346 (99.7%) of them. One adolescent (0.3%) was vegetarian. The average number of meals per day was 2.59 &#177; 0.5 with extremes of 1 and 4 meals per day.</p><p>One hundred and forty adolescents (40.6%) consumed less than 3 meals per day.</p><p>All adolescents included in this study had already been hospitalized at least once, 19.3% of whom had more than five hospitalizations per year.</p><p>The average number of hospitalizations per year was 4.15 &#177; 1.8 with extremes of 1 and 12 hospitalizations/year. Three hundred and twenty-six adolescents (93.9%) had already been transfused. The average number of blood transfusions was 3.7 &#177; 2.6 with extremes of 1 and 18 transfusions.</p><p>The mean age at the time of the first blood transfusion was 5.07 &#177; 3.2 years with extremes of 18 months and 17 years. In our study the main causes of</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of adolescents by age groups</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >N</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Age range (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[10 - 13[</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >18.7</td></tr><tr><td align="center" valign="middle" >[13 - 16[</td><td align="center" valign="middle" >116</td><td align="center" valign="middle" >33.4</td></tr><tr><td align="center" valign="middle" >[16 - 19]</td><td align="center" valign="middle" >166</td><td align="center" valign="middle" >47.9</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >347</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><p>n: partial workforce; %: percentage.</p><p>hospitalizations were vaso-occlusive and anemic crises. The distribution of adolescents according to the type of acute complications is shown in <xref ref-type="table" rid="table2">Table 2</xref>. Adolescents who had vaso-occlusive crises numbered 345. The number of episodes of these bone CVOs was less than or equal to 3 in 240 cases (69.6%); in 105 cases (29.8%), it was greater than 3.</p><p>Adolescents presented with acute chest syndrome in 29 cases (8.4%). Priapism was observed in 54 cases (29.7%). The strokes were all ischemic, and observed in 18 cases (5.2%). The distribution of adolescents according to the type of chronic complications is shown in <xref ref-type="table" rid="table3">Table 3</xref>. It is mainly gallbladder lithiasis in 145 cases (41.8%), followed by osteonecrosis of the femoral head in 43 cases (12.4%).</p><p>One hundred and fifty-two (43.8%) adolescents had good nutritional status (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Stature growth was normal in 192 cases (55.3%) and 155 (44.7%) adolescents had growth delay.</p><p>Growth retardation was severe in 55 (15.9%) adolescents with a T/A ratio lower than minus 3 SD according to new WHO growth standards.</p><p>In girls, the average age of onset of breast development, also called thelarche, was 13.09 &#177; 1.7 years with extremes of 10 and 16 years. One hundred and eleven</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of adolescents by type of acute complications</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Acute complications</th><th align="center" valign="middle" >Presence of complications n (%)</th><th align="center" valign="middle" >Lack of complications n (%)</th></tr></thead><tr><td align="center" valign="middle" >Bone CVO</td><td align="center" valign="middle" >345 (99.4)</td><td align="center" valign="middle" >2 (0.6)</td></tr><tr><td align="center" valign="middle" >Anemic crisis</td><td align="center" valign="middle" >326 (93.9)</td><td align="center" valign="middle" >21 (6.1)</td></tr><tr><td align="center" valign="middle" >Priapism</td><td align="center" valign="middle" >54 (29.7)</td><td align="center" valign="middle" >128 (70.3)</td></tr><tr><td align="center" valign="middle" >STA</td><td align="center" valign="middle" >29 (8.4)</td><td align="center" valign="middle" >318 (91.6)</td></tr><tr><td align="center" valign="middle" >AVC</td><td align="center" valign="middle" >18 (5.2)</td><td align="center" valign="middle" >329 (94.8)</td></tr></tbody></table></table-wrap><p>n: Partial workforce; %: Percentage; CVO: Vaso-occlusive crisis; ATS: Acute chest syndrome; Stroke: Acute vascular accident.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Distribution of adolescents by type of chronic complications</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  colspan="2"  >Presence of chronic complications</th><th align="center" valign="middle"  colspan="2"  >Absence of chronic complications</th></tr></thead><tr><td align="center" valign="middle" >N</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >N</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle" >Vesicular lithiasis</td><td align="center" valign="middle" >145</td><td align="center" valign="middle" >41.8</td><td align="center" valign="middle" >202</td><td align="center" valign="middle" >58.2</td></tr><tr><td align="center" valign="middle" >Osteonecrosis of the femoral head</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >12.4</td><td align="center" valign="middle" >304</td><td align="center" valign="middle" >87.6</td></tr><tr><td align="center" valign="middle" >Chronic osteomyelitis</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >315</td><td align="center" valign="middle" >90.8</td></tr><tr><td align="center" valign="middle" >Leg ulcer</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >342</td><td align="center" valign="middle" >98.6</td></tr><tr><td align="center" valign="middle" >Heart failure</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >342</td><td align="center" valign="middle" >98.6</td></tr><tr><td align="center" valign="middle" >Nephropathy</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.6</td><td align="center" valign="middle" >345</td><td align="center" valign="middle" >99.4</td></tr></tbody></table></table-wrap><p>n: partial workforce; %: percentage.</p><p>adolescents (67.3%) had already started puberty.</p><p>The average age of onset of menarche was 15.95 &#177; 1.8 years with a range of 13 and 18 years. During the study period, fifty-six adolescent girls (33.9%) already had their first menstruation.</p><p>In boys, the average age of appearance of spermarche was 15.76 &#177; 1.3 years with extremes of 13 and 18 years. Forty-six adolescents (13.3%) had already had their first ejaculation.</p><p>In both sexes, the average age of pubarche was 13.91 &#177; 1.7 years with extremes of 10 and 18 years. During our study, 196 adolescents (56.5%) had normal pubertal development for their age. An abnormality of pubertal development was found in 151 adolescents, or 43.5%.</p><p>The distribution of adolescents according to pubertal development is shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><p>From sociodemographic point, among the 54 orphan adolescents, those with delayed puberty (34) were significantly more numerous (<xref ref-type="table" rid="table3">Table 3</xref>) than those</p><p>with normal puberty, numbering 20 (p = 0.00127). Under-nutrition in our series was correlated with pubertal delay (<xref ref-type="table" rid="table3">Table 3</xref>), since among the 137 adolescents having less than 3 meals/day, 80 had pubertal delay compared to 57 with normal puberty (p = 0.0000).</p><p>Clinically in our series, frequent hospitalizations (more than 5 hospitalizations/year) contributed to pubertal delay (<xref ref-type="table" rid="table4">Table 4</xref>), since pubertal delay was significantly more observed in 39 cases compared to 25 cases with normal puberty among hospitalized adolescents more than 5 times/year (p = 0.0013). pubertal delay was significantly greater (p = 0.0000) than cases of normal puberty in the category of adolescents having had more than 3 vaso-occlusive crises/year. Blood transfusion allowed normal puberty in 176 adolescents compared to 147 with delayed puberty (p = 0.0002).</p><p>However, when the transfusions were frequent (more than 5 since the discovery of the disease), pubertal delay was significantly more reported in 37 cases, compared to 26 with normal puberty (p = 0.0127) (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>Among the adolescents who experienced priapism (<xref ref-type="table" rid="table5">Table 5</xref>), 28 had delayed puberty compared to 24 with normal puberty (p = 0.04). Wasting also contributed</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Correlation between pubertal delay and clinical aspects</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  ></th><th align="center" valign="middle" >PD</th><th align="center" valign="middle" >NP</th><th align="center" valign="middle" >OR</th><th align="center" valign="middle" >95% CI</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Age at diagnosis</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >≤5 years</td><td align="center" valign="middle" >109</td><td align="center" valign="middle" >155</td><td align="center" valign="middle" >0.9</td><td align="center" valign="middle" >0.5 - 1.6</td><td align="center" valign="middle"  rowspan="2"  >0.7734</td></tr><tr><td align="center" valign="middle" >&gt;5 years*</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >0.6 - 1.9</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Number of hospitalizations/year</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >&gt; 5</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >2.4</td><td align="center" valign="middle" >1.4 - 4.3</td><td align="center" valign="middle" >0.0013</td></tr><tr><td align="center" valign="middle" >≤5*</td><td align="center" valign="middle" >109</td><td align="center" valign="middle" >171</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Number of bone CVO/year</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >&gt; 3</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >2.7</td><td align="center" valign="middle" >1.6 - 4.3</td><td align="center" valign="middle" >0.0000</td></tr><tr><td align="center" valign="middle" >≤3*</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >155</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Blood transfusion</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >147</td><td align="center" valign="middle" >176</td><td align="center" valign="middle" >16.7</td><td align="center" valign="middle" >2.2 - 125.9</td><td align="center" valign="middle" >0.0002</td></tr><tr><td align="center" valign="middle" >No*</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Age of first transfusion</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >≤12 months</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >0.6 - 3.2</td><td align="center" valign="middle" >0.3734</td></tr><tr><td align="center" valign="middle" >&gt;12 months*</td><td align="center" valign="middle" >133</td><td align="center" valign="middle" >164</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="3"  >Number of transfusions since discovery</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >&gt;5</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >2.03</td><td align="center" valign="middle" >1.2 - 3.6</td><td align="center" valign="middle" >0.0127</td></tr><tr><td align="center" valign="middle" >≤5*</td><td align="center" valign="middle" >110</td><td align="center" valign="middle" >150</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>PD: Pubertal Delay; NP: Normal Puberty; OR: Odds ratio; CI: Confidence interval; * Reference CVO: Vaso-occlusive crisis.</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Correlation between pubertal delay and clinical aspects (2)</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  ></th><th align="center" valign="middle" >PD</th><th align="center" valign="middle" >PN</th><th align="center" valign="middle" >OR</th><th align="center" valign="middle" >95% CI</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Priapism</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >1.9</td><td align="center" valign="middle" >1.02 - 3.8</td><td align="center" valign="middle" >0.04</td></tr><tr><td align="center" valign="middle" >No*</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >STA</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >0.5 - 2.5</td><td align="center" valign="middle" >0.7041</td></tr><tr><td align="center" valign="middle" >No*</td><td align="center" valign="middle" >135</td><td align="center" valign="middle" >181</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >ONTF</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >0.6 - 2.2</td><td align="center" valign="middle" >0.6213</td></tr><tr><td align="center" valign="middle" >No*</td><td align="center" valign="middle" >128</td><td align="center" valign="middle" >173</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >WTO</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >1.3</td><td align="center" valign="middle" >0.6 - 2.7</td><td align="center" valign="middle" >0.5271</td></tr><tr><td align="center" valign="middle" >No*</td><td align="center" valign="middle" >133</td><td align="center" valign="middle" >180</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Gallstone lithiasis</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >0.7 - 1.7</td><td align="center" valign="middle" >0.7442</td></tr><tr><td align="center" valign="middle" >No*</td><td align="center" valign="middle" >85</td><td align="center" valign="middle" >116</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Splenectomy</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >0.8 - 2.5</td><td align="center" valign="middle" >0.2811</td></tr><tr><td align="center" valign="middle" >No*</td><td align="center" valign="middle" >123</td><td align="center" valign="middle" >171</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >YOUR</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Delay</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >1.7</td><td align="center" valign="middle" >1.1 - 2.7</td><td align="center" valign="middle" >0.0109</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Normal*</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >121</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >BMI/A</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Emaciation</td><td align="center" valign="middle" >113</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >4.7</td><td align="center" valign="middle" >2.9 - 7.5</td><td align="center" valign="middle" >0.0000</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Normal*</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >116</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >SMG</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >1.7</td><td align="center" valign="middle" >0.8 - 3.5</td><td align="center" valign="middle" >0.1749</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >No *</td><td align="center" valign="middle" >108</td><td align="center" valign="middle" >158</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>ATS: Acute chest syndrome; ONTF: Osteonecrosis of the femoral head, OMC: Chronic osteomyelitis.; SMG: splenomegaly.</p><p>to pubertal delay, since in the group of wasted adolescents, pubertal delay was observed in 113 cases compared to 80 cases of normal puberty (p = 0.0000). (<xref ref-type="table" rid="table5">Table 5</xref>)</p></sec><sec id="s4"><title>4. Discussion</title><p>To carry out this study, a total of 347 adolescents were selected. Our sample size is larger than that of two previous studies carried out in Brazzaville by Mpemba Loufoua et al.: 72 cases and 53 cases respectively [<xref ref-type="bibr" rid="scirp.129264-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref14">14</xref>]</p><p>The average age of the adolescents was 15.1 &#177; 2.5 years. Adolescents aged 16 to 19 are the most represented; our results are similar to those of Adeyemo et al. in Nigeria who reported a mean age of 16.0 &#177; 1.5 years in their series [<xref ref-type="bibr" rid="scirp.129264-ref15">15</xref>] . The predominance of boys reported by Minto’o Rogomb&#233; et al. in Gabon and Bah et al. in Mali was confirmed by this study, in which boys were the most represented [<xref ref-type="bibr" rid="scirp.129264-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref17">17</xref>] . However, Simo et al. in Congo and Aloni et al. in the DRC reported a predominance of females [<xref ref-type="bibr" rid="scirp.129264-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref19">19</xref>] . On this, sickle cell anemia is a genetic disease without gender predominance due to its autosomal transmission and its recessive nature. The differences observed between surveys could be linked to the demographics of each survey location or even to recruitment biases.</p><p>Orphaned adolescents represented 16.1% of the study population, contrary to the data reported by Ollandzobo et al.: 32.5%. [<xref ref-type="bibr" rid="scirp.129264-ref20">20</xref>] . The methodological difference is surely the most plausible explanation.</p><p>The majority of adolescents in this study (51%) were followed by the national sickle cell reference center (CNRDr). These results illustrate the interest of this specialized center in our health system, more specifically in the management of sickle cell disease. Vaso-occlusive and anemic crises are the main causes of hospitalization of adolescents living with homozygous sickle cell disease in Brazzaville in 99.4% and 93.9% respectively. This trend has already been reported in Brazzaville by Mbika Cardorelle et al.: 52.5% and 47% respectively [<xref ref-type="bibr" rid="scirp.129264-ref21">21</xref>] . Chronic complications were dominated by gallstone lithiasis (41.8%). This result is similar to that reported by Ngolet et al. where gallbladder lithiasis represented 40.3%. [<xref ref-type="bibr" rid="scirp.129264-ref22">22</xref>]</p><p>Adolescents with sickle cell disease have normal pubertal development (56.5%). Mandese et al. in Italy, report a prevalence of 50% [<xref ref-type="bibr" rid="scirp.129264-ref5">5</xref>] . The improving therapeutic progress in management of sickle cell anemia as well as the establishment of specialized centers in recent decades have improved the pubertal development of adolescents.</p><p>Furthermore, the prevalence of abnormalities of pubertal development was 43.5%, including 42.6% pubertal delay and 0.9% impuberty. The prevalence of pubertal delay in our study is lower than that reported by Mabiala Babela et al.</p><p>in Congo which reports a prevalence of 53.7% [<xref ref-type="bibr" rid="scirp.129264-ref10">10</xref>] . The improvement in monitoring and ECP through the intensification of treatment with the use of hydroxyurea in recent years in Congo may explain the improvement in pubertal development in adolescents living with sickle cell disease. However, efforts are still needed to reduce the prevalence of this pubertal delay to lower levels as reported by &#214;zen in Turkey: 8% [<xref ref-type="bibr" rid="scirp.129264-ref4">4</xref>] .</p><p>In our series, delayed puberty affected 21.5% of boys and 21.1% of girls. In Congo, the studies carried out report prevalence higher than those of ours: 30.2% and 42% respectively among boys and girls [<xref ref-type="bibr" rid="scirp.129264-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref14">14</xref>] . This disparity could be justified by improvement in the care of patients living with sickle cell disease over the years. In fact, Mpemba-Loufoua’s studies date back more than two decades as well as the small size of the sample.</p><p>As for impuberty, it was found in 0.9% of our study population, only among boys. Some authors consulted reported prevalence higher than ours varying from 25% to 75% [<xref ref-type="bibr" rid="scirp.129264-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref14">14</xref>] . The size of the sample as well as the methodology of each study would justify this disproportion. Nevertheless, there is consistency in the results on the predominance of gender; men are more immature than girls.</p><p>Puberty began on average at the age of 13.09 years in girls and menarche appeared on average at the age of 15.9 years. Our results are consistent with those described in the literature: the average age of onset of puberty is delayed by two years compared to adolescents without sickle cell disease [<xref ref-type="bibr" rid="scirp.129264-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.129264-ref25">25</xref>] . On the other hand, the data reported in Italy indicate an average age of menarche of 12.8 years [<xref ref-type="bibr" rid="scirp.129264-ref5">5</xref>] . This discordance could be justified by the secular advance but also the genetic, nutritional and psychosocial factors of the populations. The pubertal delay estimated at 42.6% in this work, is associated with several factors including: under-nutrition with a number of daily meals less than three, the number of hospitalizations greater than 5 per year.</p><p>Under-nutrition is a factor hindering the growth and development of Congolese adolescents: 40.6% in this study. According to the Congo Demographic Health Survey (EDS) 2012, 23% of households have inadequate food consumption, preventing them from leading a healthy and active life [<xref ref-type="bibr" rid="scirp.129264-ref26">26</xref>] .</p><p>Similarly, in its 2018 annual report, the United Nations Children’s Fund (UNICEF), reports that 149 million children worldwide are stunted, nearly 50 million are wasted and more than 340 Million suffer from a deficiency in essential micronutrients, also known as “hidden hunger” [<xref ref-type="bibr" rid="scirp.129264-ref27">27</xref>] . Thus, under-nutrition associated with sickle cell anemia, a hypermetabolic pathology due to the increased energy expenditure it requires, hinders the maturation of organs and therefore pubertal development.</p><p>The number of hospitalizations beyond five constitutes in our study a factor associated with RP. Nineteen percent of adolescents had more than 5 hospitalizations/year. M’pemba-Loufoua in his series reported the average number of hospitalizations greater than 5 per year was statistically significant (p = 0.033) [<xref ref-type="bibr" rid="scirp.129264-ref14">14</xref>] . Frequent hospitalization is often a reflection of the severe form of the disease; it is caused by episodes of recurrent CVO and frequent deglobulization crises leading to anorexia and psychological distress with the consequence of having an impact on growth and pubertal development. Our study had experienced pitfalls including the lack of funding which did not allow the realization of biological explorations such as hormonal balances that could have informed the dynamics of these parameters during puberty in adolescents living with homozygous sickle cell disease. The diagnosis of puberty was therefore only clinical, based on Tanner’s classification.</p><p>Also, the transversal nature of the study gives only a reflection of an instantaneous photograph. A long-term longitudinal study would be wise and preferable to determine the dynamics of puberty in sickle cell adolescents as it is a process.</p></sec><sec id="s5"><title>5. Conclusions</title><p>The study of the pubertal development of Congolese adolescents living with homozygous sickle cell disease confirmed the hospital statistical variabilities observed throughout the world. These variations could be explained by the fact that the factors hindering pubertal development are intrinsic (sickle cell disease with its clinical forms, its complications) and extrinsic (environmental: diet, social status).</p><p>The onset of secondary sexual characteristics is delayed by an average of two years compared to the general population. The factors associated with pubertal delay in our context are: fewer than three meals a day, a number of hospitalizations greater than 5 per year, Systematic screening of these associated factors during the follow-up of prepubertal children living with homozygous sickle cell disease is required in order to establish a prognostic score for delayed puberty.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Mbamognoua, N.G.A., Edzan, J.C., Mawa, F.O.E., Kambourou, J., Ngolet, L.O. and Monabeka, H.G. (2023) Correlation between Pubertal Delay in Adolescents with Homozygous Sickle Cell Disease and Socio-Demographic, Clinical Factors. Open Journal of Endocrine and Metabolic Diseases, 13, 173-189. https://doi.org/10.4236/ojemd.2023.1310014</p></sec><sec id="s8"><title>Appendix I: Survey Form</title><p>SURVEY SHEET</p><p>SHEET N˚/____/ DATE OF SURVEY___/___/___</p>I. Identify<p>Gender: Male /__/ Female /__/</p><p>Date of Birth: ___/__/_____ Age: /____/ years</p><p>Level of education: Primary /__/ Secondary 1<sup>st</sup> degree /__/ Secondary 2<sup>nd</sup> degree /__/ Higher /__/ Not at school /__/</p><p>Residence: Mak&#233;l&#233;k&#233;l&#233; /__/ Bacongo /__/ Poto-Poto /__/ Moungali /__/ Ouenz&#233; /__/ Talanga&#239; /__/</p><p>Mfilou /__/ Madibou /__/ Djiri /__/ Mbamou Island /__/</p><p>Carergiver: Father /__/ Mother /__/ Guardian /__/ (Specify_______________)</p><p>Social Status: Orphan /__/ Not orphan /__/ If yes: Father /__/ Mother /__/ Two-parent /___/</p><p>Consultation center: CNRD /__/ PGE /__/ CME /__/</p>II. History<p>1. Natural history of sickle cell disease</p><p>- Age at diagnosis: 1st year of life /__/ 1 - 5 years /__/ 6 - 10 years /__/ ≥10 years/__/</p><p>- Circumstance of discovery: Screening /__/ CVO /__/ Anemic crisis /__/ Hand-foot syndrome/__/ Other (Specify_________________________________)</p><p>- Electrophoretic profile: % HbS /___/ % HbA2 /___/ % HbF /___/ % Other /______/</p><p>- Baseline hemoglobin level: /_________/ g/dl</p><p>- Acute complications:</p><p>o Number of CVOs per year: /___/</p><p>o Number of anemic attacks since birth: /___/</p><p>o Blood transfusion: Yes /__/ No /__/</p><p>If yes, Age of first TS /_____/(months/years) Number since birth: /___/</p><p>o Has he ever had a stroke: Yes /__/ No /__/</p><p>If yes, Number since discovery of the disease: /__/ Type: /______________/</p><p>o Has he ever had acute chest syndrome: Yes /__/ No /__/</p><p>If yes, number since discovery of the disease: /__/</p><p>o Has he ever had priapism: Yes /__/ No /__/</p><p>If yes, number since discovery of the disease: /__/</p><p>- Chronic complications:</p><p>o Heart failure: Yes /__/ No /__/</p><p>o Osteonecrosis of the femoral head: Yes /__/ No /__/</p><p>o Chronic osteomyelitis: Yes /__/ No /__/</p><p>o Leg ulcer: Yes /__/ No /__ /</p><p>o Gallbladder lithiasis: Yes /__/ No /__ /</p><p>o Nephropathy: Yes /__/ No /__ /</p><p>- Splenectomy: Yes /__/ No /__/</p><p>- Hospitalization: Yes /__/ No /__/</p><p>If Yes, average number of hospitalizations per year: /__/</p><p>- Monitoring quality: Regular /__/ Irregular /__/</p><p>- Maintenance treatment:</p><p>o Folic acid: Yes /__/ No /__/</p><p>If yes, Regular /__/ Irregular /__/</p><p>Number of tablets/day /___/</p><p>o Hydroxy urea: Yes /__/ No /__/</p><p>If yes,</p><p>Indication:/______________________________/ Start date:/______________/</p><p>o Transfusion Exchange: Yes/__/ No /___/</p><p>If yes, Indication: /________________________/ Number: /___/</p><p>- Marrow transplant: Yes/___/ No /___/</p><p>If yes, When: /___/</p><p>- Vaccination:</p><p>o Thyphim VI Yes /__/ No /__/</p><p>o Pneumo23 Yes /__/ No /__/</p><p>o Meningococcus Yes /__/ No /__/</p><p>o Anti-influenza Yes /__/ No /__ /</p><p>2. Other personal history</p><p>- Thelarche (in girls) Yes/__ / No/__/</p><p>o If yes, age of onset: /___/ years</p><p>- Menarche (in girls): Yes /__/ No /__/</p><p>o If yes, age of onset: /___/ years</p><p>- Spermarch (in boys): Yes /__/ No /__/</p><p>o If yes, age of onset: /___/ years</p><p>- Pubarche: Yes /__/ No /__/</p><p>o If yes, age of onset /___/ years</p><p>- Food :</p><p>o Diet: Normal (varied) /__/ Vegetarianism /__/ Veganism /__/</p><p>o Number of meals/day: 1 /__/ 2 /__/ 3 /__/</p><p>- Drinking alcohol: Yes /__/ No /__/</p><p>3. Family history</p><p>- Size of Sibling: /__/ Position in Sibling: /__/</p><p>- Number of other homozygous sickle cell children: /__/</p><p>- Marital status of parents: Couple /__/ Single /__/ Recomposed /__/</p><p>Socio-economic level: Low /__/ Medium /__/ High /__/</p>III. Physical Examination<p>1. Anthropometric measurements</p><p>- Weight: /___/ Kg Height: /___/ m BMI: /____/ Kg/m <sup>2</sup></p><p>- T/A: /____/ SD Either</p><p>- Normal /___/</p><p>- Growth retardation /___/</p><p>- Significant growth retardation /___/</p><p>- BMI / A: /___/ SD Either</p><p>- Normal /___/</p><p>- Wasting /___/</p><p>- Severe wasting /___/</p><p>- Overweight /___/</p><p>- Obesity /___/</p><p>2. Coloring of the mucous membranes</p><p>- Normal /__/ Pallor: Slight /__/ Moderate /__/ Clear /__/</p><p>3. Jaundice: Yes /__/ No /__/ If yes, Mild /__/ Moderate /__/ Frank /__/</p><p>4. Splenomegaly: Yes /__/ No /__/ If yes, Hackett stage: I; II; III; IV</p></sec><sec id="s9"><title>Appendix II: Growth Indicators According to WHO (Z Score)</title><disp-formula id="scirp.129264-formula1"><graphic  xlink:href="//html.scirp.org/file/1-1980453x4.png?20231201163029107"  xlink:type="simple"/></disp-formula></sec><sec id="s10"><title>Appendix III: TANNER classification</title><p>Girl: S /__/ S /__/ Boy: P /__/ G /__/</p><p>Precocious puberty /__/ Pubertal delay /__/ Normal puberty /__/ Impuberty /__/</p><p>For the girl:</p><p>S1P1: Impubescent stage</p><p>S2P2: The average age is around 10&#189; to 11 &#177; 2 years</p><p>S3P3: The average age is around 12 &#177; 2 years</p><p>S4P4: The average age is around 13 &#177; 2 years</p><p>S5P5: The average age is around 14&#189; &#177; 3 years</p><p>In the boy:</p><p>G1P1: Impubescent stage</p><p>G2: The average age is around 11&#189; &#177; 1 years &amp; P2, the average age is 13&#189; years</p><p>G3: The average age is around 12&#189; &#177; 2 years &amp; P3, the average age is 14 years</p><p>G4: The average age is around 13&#189; &#177; 2 years &amp; P4 the average age is 14&#189; years</p><p>G5P5: The average age is around 15 &#177; 2 years</p></sec></body><back><ref-list><title>References</title><ref id="scirp.129264-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bourrillon, A., Benoist, G., Chabrol, B., Chéron, G. and Grimprel, E. (2020) Pediatrics for the Practitioner. 7th Edition, Elsevier Masson, Amsterdam, 824 p.</mixed-citation></ref><ref id="scirp.129264-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Busiah, K., Belien, V., Dallot, N., Fila, M., Guilbert, J., Harroche, A., et al. (2007) Diagnosis of Pubertal Delays. Archives of Pediatrics, 14, 1101-1110. https://doi.org/10.1016/j.arcped.2007.05.012</mixed-citation></ref><ref id="scirp.129264-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2010) Sickle Cell Disease: A Strategy for the WHO African Region. WHO AFR/RC60/8.</mixed-citation></ref><ref id="scirp.129264-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">&amp;#214;zen, S., &amp;#220;nal, S., Er&amp;#231;etin, N. and Ta&amp;#351;delen, B. (2013) Frequency and Risk Factors of Endocrine Complications in Turkish Children and Adolescents with Sickle Cell Anemia. Turkish Journal of Haematology, 30, 25-31. https://doi.org/10.4274/tjh.2012.0001</mixed-citation></ref><ref id="scirp.129264-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Mandese, V., Bigi, E., Bruzzi, P., Palazzi, G., Predieri, B., Lucaccioni, L., et al. (2019) Endocrine and Metabolic Complications in Children and Adolescents with Sickle Cell Disease: An Italian Cohort Study. BMC Pediatrics, 19, 56-65. https://doi.org/10.1186/s12887-019-1423-9</mixed-citation></ref><ref id="scirp.129264-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Aschroft, M.T., Serjeant, G.R. and Desai, P. (1972) Heights, Weights and Skeletal Age of Jamaican Adolescents with Sickle Cell Anemia. Archives of Disease in Childhood, 47, 519-524. https://doi.org/10.1136/adc.47.254.519</mixed-citation></ref><ref id="scirp.129264-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Soliman, A.T., Zalabany, M., Amer, M. and Ansari, B.M. (1999) Growth and Pubertal Development in Transfusion-Treated Children and Adolescents with Thalassemia Major and Sickle Cell Disease: A Comparative Study. Journal of Pediatrics, 45, 23-30. https://doi.org/10.1093/tropej/45.1.23</mixed-citation></ref><ref id="scirp.129264-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Uchendu, U.O., Ikefuna, A.N., Nwokocha, A.R.C. and Emodi, I.J. (2010) Impact of Socioeconomic Status on Sexual Maturation of Nigerian Boys Living with Sickle Cell Anemia. Hematology, 15, 414-421. https://doi.org/10.1179/102453310X12647083621209</mixed-citation></ref><ref id="scirp.129264-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">M’Pemba-Loufoua, A.B., Nzingoula, S., Moubouh-Akouala, F. and Oba, A. (2001) Pubertal Development in Homozygous Sickle Cell Girls. About 72 Cases. Bulletin de la Société de Pathologie Exotique, 94, 326-329.</mixed-citation></ref><ref id="scirp.129264-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mabiala Babela, J., Mberi, F., Ikobo, L.C., Nika, E., Ngoulou, B. and Missambou Mandilou, S.V. (2018) The Quality of Life of Adolescents with Homozygous Sickle Cell Disease Followed at the Brazzaville University Hospital (Congo). Bulletin of the Exotic Pathology Society, 111, 46-50. https://doi.org/10.3166/bspe-2018-0006</mixed-citation></ref><ref id="scirp.129264-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Nartey, E.B., Spector, J., Adu-Afarwuah, S., Jones, C.L., Jackson, A., Ohemeng, A., et al. (2021) Nutritional Perspectives on Sickle Cell Disease in Africa: A Systematic Review. BMC Nutrition, 7, Article No. 9. https://doi.org/10.1186/s40795-021-00410-w</mixed-citation></ref><ref id="scirp.129264-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zemel, B.S., Kawchak, D.A., Ohene-Frempong, K., Schall, J.I. and Stallings, V.A. (2007) Effects of Delayed Pubertal Development, Nutritional Status, and Disease Severity on Longitudinal Patterns of Growth Failure in Children with Sickle Cell Disease. Pediatric Research, 61, 607-613. https://doi.org/10.1203/pdr.0b013e318045bdca</mixed-citation></ref><ref id="scirp.129264-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2019) Global Strategy for Women’s, Children’s and Adolescents’ Health (2016-2030): Report of the Director-General. World Health Organization, Geneva.</mixed-citation></ref><ref id="scirp.129264-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">M’Pemba-Loufoua, A.B. and Nzingoula, S. (2001) Pubertal Development in Homozygous Congolese Sickle Cell Patients. Black African Medicine, 6, 5-10.</mixed-citation></ref><ref id="scirp.129264-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Adeyemo, T.A., Ojewunmi, O.O., Diaku-Akinwumi, I.N., Ayinde, O.C. and Akanmu, A.S. (2015) Health Related Quality of Life and Perception of Stigma in Adolescents Living with Sickle Cell Disease in Nigeria: A Cross Sectional Study. Pediatric Blood &amp; Cancer, 62, 1245-1251. https://doi.org/10.1002/pbc.25503</mixed-citation></ref><ref id="scirp.129264-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Minto’o Rogombé, S., Kuissi Kamgaing, E., Minko, J.I., Mimbila Mayi, M., Nkoghe, V.C., Koko, J., et al. (2018) Medical Follow-Up and Schooling of Children with Sickle Cell Disease in Gabon. Health Sciences and Diseases, 19, 74-78.</mixed-citation></ref><ref id="scirp.129264-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Bah, A., Bagayoko, T., Kassogué, A., Thiéro, A., Koné, S., Samaké, B., et al. (2021) Epidemiological and Clinical Aspects of Sickle Cell Disease in Children at the Nianankoro Fomba Hospital in Ségou. Mali Public Health, 11, 101-106. https://doi.org/10.53318/msp.v11i1.1901</mixed-citation></ref><ref id="scirp.129264-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Simo, L.J., Ocko Gokaba, T.L., Kocko, I., Malanda, F., Njopwouo, M.S., Atipo Galiba, O.F.G., et al. (2019) Monitoring of Sickle Cell Patients at the National Reference Center for Sickle Cell Disease in Brazzaville (January 2016-June 2017). Health Sciences and Disease, 20, 97-104.</mixed-citation></ref><ref id="scirp.129264-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Aloni, M. and Nkee, L. (2014) Challenge of Managing Sickle Cell Disease in a Pediatric Population Living in Kinshasa, Democratic Republic of Congo: A Sickle Cell Center Experience. Hemoglobin, 38, 196-200. https://doi.org/10.3109/03630269.2014.896810</mixed-citation></ref><ref id="scirp.129264-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ollandzobo Ikobo, L., Mouyabi Mberi, F., Nika, E., Missambou, M., Ngoulou, B., M’Pemba-Loufoua, A., et al. (2019) Monitoring and Health Status of Adolescents Suffering from Sickle Cell Anemia in Brazzaville (Congo). Bulletin de la Société de Pathologie Exotique, 112, 213-219.</mixed-citation></ref><ref id="scirp.129264-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Mbika Cardorelle, A. and Mouko, A. (2009) Management of Children with Sickle Cell Disease: Experience of Brazzaville. Black African Medicine, 56, 421-424.</mixed-citation></ref><ref id="scirp.129264-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ngolet, L.O., Okouango Nguelongo Ova, J., Ntsiba, H. and Elira Dokekias, A. (2017) Les complications chroniques du sujet drépanocytaire adulte à Brazzaville. Health Sciences and Disease, 18, 56-59.</mixed-citation></ref><ref id="scirp.129264-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Serjeant, G.R., Singhal, A. and Hambleton, I. (2001) Sickle Cell Disease and Age at Menarche in Jamaican Girls: Observations from a Cohort Study. Archives of Disease in Childhood, 85, 375-378. https://doi.org/10.1136/adc.85.5.375</mixed-citation></ref><ref id="scirp.129264-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Carvalho, F.A., Souza, A.I., Ferreira, A.L., Da Silva Neto, S., Oliveira, A.C., Gomes, M.L., et al. (2017) Profile of Reproductive Issues Associated with Different Sickle Cell Disease Genotypes. Revista Brasileira de Ginecologia e Obstetrícia, 39, 397-402. https://doi.org/10.1055/s-0037-1604179</mixed-citation></ref><ref id="scirp.129264-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Stimpson, S.J., Rebele, E.C. and DeBaun, M.R. (2016) Common Gynecological Challenges in Adolescents with Sickle Cell Disease. Expert Review of Hematology, 9, 187-196. https://doi.org/10.1586/17474086.2016.1126177</mixed-citation></ref><ref id="scirp.129264-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">National Center for Statistics and Economic Studies (2012, February) Congo Demographic and Health Survey EDSC-II 2011-2012. Statistics and Economic Studies, 38. https://www.cnsee.org</mixed-citation></ref><ref id="scirp.129264-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">United Nations Children’s Fund (2020) The State of the World’s Children 2019: Children, Food and Nutrition-Growing up Well in a Changing World. United Nations, New York.</mixed-citation></ref></ref-list></back></article>